“Gene Therapy”

13 result(s)
Drug Pipeline
A Q2 2022 Look at Projected Gene Therapies and Approval Timelines
A Q2 2022 Look at Projected Gene Therapies and FDA Approval Timelines More
Briefing
Drug Pipeline
Treatment Options Expand in Robust Gene Therapy Pipeline
New Gene Therapies for Sickle Cell Disease, Hemophilia on the Horizon More
Briefing
Drug Pipeline
Expanding Therapies, Indications and Implications for Payors
2022 Marketplace Outlook: Expanding Therapies, Indications and Implications for Payors More
Briefing
Drug Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline More
Briefing
Health Equity
Great Strides in Managing Sickle Cell Disease
Great strides are being made in managing sickle cell disease to address patient pain and payor costs. More
Commentary
Drug Pipeline
Gene Therapies in the Pipeline Highlight a Variety of Conditions and Anticipated Treatments
The gene therapy pipeline report highlights what payors can expect for a variety of conditions. More
Briefing
Near-Term Outlook for Projected Gene Therapies and Their Approval Timelines | Payor Solutions
Drug Pipeline
Near-Term Outlook for Projected Gene Therapies and Their Approval Timelines
Projected Approvals of Pipeline Gene Therapies Expected to Treat Conditions with Few Options More
Briefing
Pipeline Therapies Could Expand Choices for Conditions with Limited Options | Payor Solutions | CVS Health
Drug Pipeline
Pipeline Therapies Could Expand Choices for Conditions with Limited Options
Our periodic gene therapy report helps payor better understand the potential for these innovative treatments to transform patient care and outcomes More
Briefing
Drug Pipeline
A Thriving Pipeline Expected to Continue Expanding Treatment Options
Our periodic gene therapy report helps payor better understand the potential for these innovative treatments to transform patient care and outcomes More
Briefing
Cost Management
Solutions to Mitigate the Cost of Gene Therapies
CVS Health offers payors a new stop-loss program and installment payment plan to help mitigate the large one-time impact of costly gene therapies. These approaches are part of... More
Briefing